Researchers at Stanford have created a method to differentiate human pluripotent stem cells (hPSCs) into >90% pure hematopoietic stem cell (HSC)-like cells, which serve as progenitors to blood and immune cells.
Despite their rapidly expanding therapeutic potential, human pluripotent stem cell (hPSC)-derived cell therapies continue to have serious safety risks.